<DOC>
	<DOCNO>NCT01183247</DOCNO>
	<brief_summary>An open , single center , randomise study investigate three different immunosuppressive regimen de novo renal transplant recipient : 1. st sirolimus / EC-MPS / tacrolimus regimen - After 3 month protocol biopsy perform . If rejection detect calcineurin inhibitor ( tacrolimus ) withdrawn . 2. nd everolimus / EC-MPS / tacrolimus regimen - After 3 month protocol biopsy perform . If rejection detect calcineurin inhibitor ( tacrolimus ) withdrawn . 3. rd tacrolimus / EC-MPS / prednisone regimen - After 3 month protocol biopsy perform . If rejection detect prednisone withdrawn .</brief_summary>
	<brief_title>An Open , Single Centre , Randomised , Parallel Group Study Investigate Three Different Immunosuppressive Regimens</brief_title>
	<detailed_description>This study design show similar efficacy different adverse event profile three regimen . Its main purpose provide information , steroid free immunosuppressive treatment valuable alternative treatment de novo kidney transplant recipient possible withdraw calcineurin inhibitor 3 month steroid free protocol . A secondary rationale study compare sirolimus everolimus directly well differentiate two mTOR-inhibitors term compound-specific effect class-effects . This allow early conclusion usage two mTOR-inhibitors CNI-free regimen . Basis study follow hypothesis regard first 6 month treatment follow kidney transplantation : - Similar graft function three treatment group 6 month - No difference graft patient survival three group - No difference incidence first , total number , type acute rejection , number anti-rejection treatment three group - No difference number patient successfully withdraw calcineurin inhibitor sirolimus everolimus arm , respectively - A different adverse event profile regard incidence dyslipidemias , impair fast glucose , new onset diabetes mellitus , de novo post-transplant insulin dependency , histological sign calcineurin inhibitor toxicity , tubulointerstitial nephrotoxicity three group . In addition incidence mTOR-inhibitor specific adverse event analyse . These hypothesis basis study objective .</detailed_description>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>1 . Male female patient 18 75 year age , regardless race . 2 . Female patient child bear age agree maintain effective birth control practice study . 3 . Patient end stage kidney disease suitable candidate primary renal transplantation retransplantation assess transplantation centre . 4 . Patient fully inform give write independent person witness oral informed consent . 1. Patient pregnant breastfeeding . 2 . Patient low immunological risk constellation , define receive kidney HLAidentical relate live donor . 3 . Patient high immunological risk constellation , define donor specific HLAantibodies and/or previous graft survival short 3 year due rejection . 4 . Patient donor positive T Bcell crossmatch . 5 . Patient donor ABO incompatible . 6 . Age donor &gt; 75 year . 7 . Cold ischemia time &gt; 36 hour . 8 . Patient leucopenia , define transplantation le 3000/mm3 leukocyte . 9 . Patient thrombocytopenia , define transplantation le 75000/mm3 thrombocyte . 10 . Patient allergic intolerant cremophor RH 60 structurally related compound , steroid , everolimus , tacrolimus , Sirolimus ECMPS . 11 . Patient donor know HIV positive . 12 . Patient significant liver disease , define past 28 day continuously ASAT ( SGOT ) and/or ALAT ( SGPT ) level great 3 fold upper value normal range investigational site . 13 . Patient malignancy history malignancy â‰¤ 2 year , except non metastatic basal squamous cell carcinoma skin treat successfully . 14 . Patient significant , uncontrolled concomitant infection and/or severe diarrhea , vomit , active peptic ulcer . 15 . Patient take take investigational drug past 28 day . 16 . Patient previously receive receive another organ transplant kidney . 17 . Patient unlikely comply visit schedule protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Everolimus ,</keyword>
	<keyword>rapamycin ,</keyword>
	<keyword>prednisone ,</keyword>
	<keyword>tacrolimus ,</keyword>
	<keyword>MMF ,</keyword>
	<keyword>steroid-free ,</keyword>
	<keyword>protocol biopsy</keyword>
</DOC>